"Life can only be understood backwards; but it must be lived forwards."
I mprovement in life expectancy of patients with congenital heart disease (CHD) (2,3) has resulted in emergence of a patient population for which there is sparse track record in adult medicine.
Tracking these outcomes is fascinating, yet problematic because CHD is not a single disease entity but an infinite combination of structural and physiological variables. As medical and surgical management has evolved, so has the patient population, due to a continually shifting selection bias. In earlier times, prostaglandin was not available to stabilize newborns with ductal-dependent lesions. Patients with chromosomal abnormalities were often excluded from surgical repair. Fetal diagnosis and neonatal transport became available in more recent times. Therefore, survivors of an earlier era represent a hardier and less complex group whereas more recent times have seen survival of a more marginally viable population.
In this issue of the Journal, Raissadati et al. (4) followed mortality after surgery for CHD for up to 60 years. This study is unique because of a remarkable 97.5% follow-up of longitudinal follow up and precisely matched normal controls provided by Finnish registries. These datasets have an advantage over hospital or insurance data, which only accounts for patients with access to care and is subject to coding variability (5) . Moreover, reliable longitudinal data cannot be tracked within a system in which patients move between insurers and institutions.
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patients with transposition of the great arteries during the later era, which coincides with a change from the atrial to the arterial switch approach. Late mortality remained high for patients with single-ventricle patients, however.
A bimodal distribution of mortality from congestive heart failure was found for most lesions, with higher mortality in the first few years of life, followed by a relatively benign course lasting more than 20 years for most simple lesions and <10 years for complex patients. This is consistent with resource utilization data from the United States that reflects a relatively stable period after the infancy, followed by increased hospitalization as they approach emerging adulthood (6,7). Raissadati et al. (4) postulate that the rising mortality could be related to transfer of care to an adult health system, but one might also argue that this pattern reflects the natural history of CHD and that patient transfer during a period of stability is well timed.
Among the non-CHD causes of death, respiratory disease was the most common with more than onehalf occurring among patients with a mental disability. Deaths due to neurological (stroke, seizures) and infectious diseases were also more prevalent than the general population. The lack of progress in mortality reduction in these categories is likely due to the superimposition of co-morbid or acquired conditions (8) (9) (10) . The importance of age-related acquired complications in the adult with CHD reinforces the importance of their care being delivered in an environment that includes the full spectrum of expertise in the recognition and treatment of both congenital and acquired diseases.
A higher incidence of cancer deaths in CHD patients reinforces previously reported concerns (11, 12) .
In the more recent era, the relative risk of cancer in we may never reach the "Finnish-line."
